Results 181 to 190 of about 282,442 (237)
Minimizing batch‐to‐batch variability of a live virus vaccine by process analytical technologies
Abstract For bioprocesses producing live virus, such as enterovirus Coxsackievirus A21, viral titer (infectivity basis) decay rates can exceed 30% within a day. Consequently, harvest timing is paramount. To optimize titer at harvest, a continuous viral product titer model was generated to elucidate kinetics.
Katherine Forrester+4 more
wiley +1 more source
Abstract Recombinant adeno‐associated virus (rAAV) is a widely used delivery vehicle in gene therapy. A scalable production technology is essential for its wide clinical applications. We have taken a synthetic biology approach to generate HEK293‐based cell lines which harbor integrated genetic elements encoding essential AAV and adenoviral helper ...
Han‐Jung Kuo+6 more
wiley +1 more source
Abstract Background Hepatocellular carcinoma (HCC) is a deadly malignancy known for its ability to evade immune surveillance. NOP2/Sun RNA methyltransferase family member 2 (NSUN2), an RNA methyltransferase involved in carcinogenesis, has been associated with immune evasion and energy metabolism reprogramming.
Jinhua Jiang+6 more
wiley +1 more source
Abstract Background Pancreatic cancer's aberrant lipid metabolism fuels cell growth, invasion, and metastasis, yet its impact on immune surveillance and immunotherapy is unclear. This study investigated how sterol regulatory element‐binding transcription factor 1 (SREBP1)‐driven lipid metabolism affects the tumor microenvironment (TME) in pancreatic ...
Mengyi Lao+12 more
wiley +1 more source
Promising Prodiginins Biological Activities
ABSTRACT Prodiginins are a large family of at least 34 pyrrolic compounds, including the well‐studied red pigment prodigiosin. Prodiginins are produced by several microorganisms displaying broad biological activities, including antimicrobial, antiviral, antiparasitic, antiproliferative, and immunosuppressive activities.
María F. Ladetto+6 more
wiley +1 more source
Abstract This Phase 1 study of ubrogepant was conducted to establish the bioequivalence (BE) of the 50‐ and 100‐mg to‐be‐marketed (TBM) tablet formulations with the clinical trial (CT) 100‐mg tablet formulation and evaluate the food effect on the bioavailability of the 100‐mg TBM tablet. This 2‐part study enrolled healthy participants aged 18‐45 years.
Ramesh Boinpally, Joel M. Trugman
wiley +1 more source